Osteopore (ASX:OSX) reported the early cessation of its AU$18.7 million dental grant clinical-industrial partnership project after a strategic review, according to a Thursday Australian bourse filing.
The decision will allow for a reallocation of resources and align with its near- and mid-term objectives of prioritizing commercialization.
The firm had been looking for opportunities to improve cost center performance while at the same time streamlining expenses.
Its shares rose 10% on market close on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.